186 related articles for article (PubMed ID: 34515878)
1. A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target.
Xu JL; Guo Y
Invest New Drugs; 2022 Feb; 40(1):58-67. PubMed ID: 34515878
[TBL] [Abstract][Full Text] [Related]
2. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer.
Li TJ; Jin KZ; Li H; Ye LY; Li PC; Jiang B; Lin X; Liao ZY; Zhang HR; Shi SM; Lin MX; Fei QL; Xiao ZW; Xu HX; Liu L; Yu XJ; Wu WD
Cancer Lett; 2022 Apr; 530():142-155. PubMed ID: 35077803
[TBL] [Abstract][Full Text] [Related]
3. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
5. Expression of CAMK1 and its association with clinicopathologic characteristics in pancreatic cancer.
Lei Y; Yu T; Li C; Li J; Liang Y; Wang X; Chen Y; Wang X
J Cell Mol Med; 2021 Jan; 25(2):1198-1206. PubMed ID: 33342045
[TBL] [Abstract][Full Text] [Related]
6. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma.
Cheng Y; Wang K; Geng L; Sun J; Xu W; Liu D; Gong S; Zhu Y
EBioMedicine; 2019 Feb; 40():382-393. PubMed ID: 30639415
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
8. Over-Expression of Alpha-Enolase as a Prognostic Biomarker in Patients with Pancreatic Cancer.
Sun L; Guo C; Cao J; Burnett J; Yang Z; Ran Y; Sun D
Int J Med Sci; 2017; 14(7):655-661. PubMed ID: 28824297
[No Abstract] [Full Text] [Related]
9. Identification of PDCD1 and PDCD1LG2 as Prognostic Biomarkers and Associated with Immune Infiltration in Hepatocellular Carcinoma.
Li W; Mei M; Liu T; Zhang S; Wang Z; Suo Y; Wang S; Liu Y; Zhang N; Lu W
Int J Gen Med; 2022; 15():437-449. PubMed ID: 35046705
[TBL] [Abstract][Full Text] [Related]
10. TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer.
Wu J; Wang Y; Jiang Z
J Gastrointest Cancer; 2021 Mar; 52(1):150-159. PubMed ID: 32077004
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of Myoferlin in Human Pancreatic Cancer via Bioinformatics.
Pi R; Chen Y; Du Y; Dong S
Biomed Res Int; 2021; 2021():2602322. PubMed ID: 34957301
[TBL] [Abstract][Full Text] [Related]
12. Comparative bioinformatical analysis of pancreatic head cancer and pancreatic body/tail cancer.
Yin L; Xiao L; Gao Y; Wang G; Gao H; Peng Y; Zhu X; Wei J; Miao Y; Jiang K; Lu Z
Med Oncol; 2020 Apr; 37(5):46. PubMed ID: 32277286
[TBL] [Abstract][Full Text] [Related]
13. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
14. Phyto-targeting the CEMIP Expression as a Strategy to Prevent Pancreatic Cancer Metastasis.
Periyasamy L; Muruganantham B; Park WY; Muthusami S
Curr Pharm Des; 2022; 28(11):922-946. PubMed ID: 35236267
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer.
Zhu HZ; Zhou WJ; Wan YF; Ge K; Lu J; Jia CK
World J Gastroenterol; 2020 Feb; 26(8):804-817. PubMed ID: 32148378
[TBL] [Abstract][Full Text] [Related]
16. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
17. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer.
Zhou X; Zhu X; Yao J; Wang X; Wang N
Invest New Drugs; 2021 Dec; 39(6):1469-1483. PubMed ID: 33983530
[TBL] [Abstract][Full Text] [Related]
19. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer.
Liu B; Fu T; He P; Du C; Xu K
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34143198
[TBL] [Abstract][Full Text] [Related]
20. KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion.
Sabe H
Cell Commun Signal; 2023 May; 21(1):106. PubMed ID: 37158894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
